JP2019510793A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510793A5
JP2019510793A5 JP2018552707A JP2018552707A JP2019510793A5 JP 2019510793 A5 JP2019510793 A5 JP 2019510793A5 JP 2018552707 A JP2018552707 A JP 2018552707A JP 2018552707 A JP2018552707 A JP 2018552707A JP 2019510793 A5 JP2019510793 A5 JP 2019510793A5
Authority
JP
Japan
Prior art keywords
alkylene
formula
group
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018552707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510793A (ja
JP7120925B2 (ja
Filing date
Publication date
Priority claimed from EP16163939.8A external-priority patent/EP3228326A1/en
Application filed filed Critical
Publication of JP2019510793A publication Critical patent/JP2019510793A/ja
Publication of JP2019510793A5 publication Critical patent/JP2019510793A5/ja
Application granted granted Critical
Publication of JP7120925B2 publication Critical patent/JP7120925B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018552707A 2016-04-05 2017-04-05 新規コンジュゲート Active JP7120925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163939.8 2016-04-05
EP16163939.8A EP3228326A1 (en) 2016-04-05 2016-04-05 Nucleic acid linked to a trivalent glycoconjugate
PCT/EP2017/058112 WO2017174657A1 (en) 2016-04-05 2017-04-05 Nucleic acid linked to a trivalent glycoconjugate

Publications (3)

Publication Number Publication Date
JP2019510793A JP2019510793A (ja) 2019-04-18
JP2019510793A5 true JP2019510793A5 (cg-RX-API-DMAC7.html) 2020-05-14
JP7120925B2 JP7120925B2 (ja) 2022-08-17

Family

ID=55697082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018552707A Active JP7120925B2 (ja) 2016-04-05 2017-04-05 新規コンジュゲート

Country Status (11)

Country Link
US (2) US10913945B2 (cg-RX-API-DMAC7.html)
EP (3) EP3228326A1 (cg-RX-API-DMAC7.html)
JP (1) JP7120925B2 (cg-RX-API-DMAC7.html)
CN (2) CN109562188B (cg-RX-API-DMAC7.html)
AU (1) AU2017245687B2 (cg-RX-API-DMAC7.html)
CA (1) CA3019981A1 (cg-RX-API-DMAC7.html)
DK (1) DK3439703T3 (cg-RX-API-DMAC7.html)
ES (1) ES2805026T3 (cg-RX-API-DMAC7.html)
HU (1) HUE049931T2 (cg-RX-API-DMAC7.html)
PL (1) PL3439703T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017174657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI859114B (zh) * 2016-04-11 2024-10-21 加拿大商艾爾布圖斯生技公司 靶向組合物
EP3385272A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Further novel oligonucleotide-ligand conjugates
WO2018185252A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Nucleic acid conjugates
EP3550022A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions
WO2018185253A1 (en) * 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Ligand modified double-stranded nucleic acids
US11015198B2 (en) * 2017-04-05 2021-05-25 Silence Therapeutics Gmbh Products and compositions
EP3483269A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
IL269517B2 (en) 2017-04-05 2025-01-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof
EP4219714A3 (en) 2017-04-05 2023-08-30 Silence Therapeutics GmbH Rna interference mediated inhibition of tmprss6
WO2019092282A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
EP3483270A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
SG11202003082UA (en) * 2017-11-13 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
US11560563B2 (en) 2018-04-05 2023-01-24 Silence Therapeutics Gmbh SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
EP3550021A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions for inhibiting expression of a target gene
EP3549610A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Nucleic acid conjugates
EP3598995A1 (en) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
AU2019380628B2 (en) 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
EP3730617A1 (en) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
WO2020104669A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
US12285439B2 (en) 2018-11-26 2025-04-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
WO2020225301A1 (en) 2019-05-07 2020-11-12 Universität Bern Nucleic acids for inhibiting expression of pros1 in a cell
WO2021037941A1 (en) 2019-08-27 2021-03-04 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
IL290766B2 (en) 2019-09-03 2026-03-01 Arcturus Therapeutics Inc Administration of therapeutically active conjugates mediated by asialoglycoprotein receptor
CN114616339A (zh) * 2019-10-24 2022-06-10 盖纳万科学有限公司 用于治疗肢端肥大症的缀合物和方法
EP4158023A1 (en) 2020-05-27 2023-04-05 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Nucleic acids for inhibiting expression of cnnm4 in a cell
CA3197198A1 (en) 2020-11-04 2022-05-12 Ute SCHAEPER Nucleic acids for inhibiting expression of pros1 in a cell
WO2022184852A1 (en) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022223557A1 (en) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of xdh in a cell
WO2022229150A1 (en) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders
US20250136977A1 (en) 2021-09-02 2025-05-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
KR20240111795A (ko) * 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
CN117580846A (zh) * 2022-04-29 2024-02-20 石药集团中奇制药技术(石家庄)有限公司 具有肝靶向递送效应的化合物及其寡聚核苷酸缀合物
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
WO2024126687A1 (en) 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
CN120981247A (zh) 2023-03-27 2025-11-18 赛伦斯治疗有限责任公司 用于干细胞移植的化合物和组合物
CN116444589B (zh) * 2023-06-15 2023-09-19 北京悦康科创医药科技股份有限公司 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法
WO2025021831A1 (en) 2023-07-24 2025-01-30 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311324D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
GB202311334D0 (en) 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
WO2025132845A1 (en) 2023-12-21 2025-06-26 Silence Therapeutics Gmbh Galnac phosphoramidites and their uses
AU2025214336A1 (en) 2024-01-29 2026-07-23 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of gpr146 in a cell
WO2025163186A1 (en) 2024-02-01 2025-08-07 Silence Therapeutics Gmbh Conjugated nucleic acids and nucleic acids comprising locked nucleosides and inverted nucleotides for inhibiting gene expression in a cell
WO2025169133A1 (en) 2024-02-09 2025-08-14 Astrazeneca Ab Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof
TW202606731A (zh) 2024-07-12 2026-02-16 瑞士商諾華公司 雙股RNAi藥劑、組成物和使用方法
US12454693B1 (en) * 2024-09-27 2025-10-28 Dexcel Pharma Technologies Ltd. Nucleic acids for inhibiting expression of transferrin receptor 2
WO2026110119A1 (en) 2024-11-25 2026-05-28 Novartis Ag Double stranded rnai agents, compositions and methods of use
WO2026132332A2 (en) 2024-12-18 2026-06-25 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of inhbe in a cell
WO2026130744A1 (en) 2024-12-19 2026-06-25 Silence Therapeutics Gmbh Nucleic acids comprising locked nucleic acids (lna) for inhibiting gene expression in a cell
WO2026133250A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133253A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026133251A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use
WO2026159213A1 (en) 2025-01-23 2026-07-30 Astrazeneca Ab Targeted lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
CA2326823A1 (en) 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
CA2889044A1 (en) * 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2015168589A2 (en) * 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
AU2015329974B2 (en) 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use

Similar Documents

Publication Publication Date Title
AU2022224779B2 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20170028074A1 (en) MultiLigand Agent for Drug Delivery
TWI811238B (zh) 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物
JP2021502120A5 (cg-RX-API-DMAC7.html)
JP2024505449A5 (cg-RX-API-DMAC7.html)
JP2022512965A5 (cg-RX-API-DMAC7.html)
JP2019536464A5 (cg-RX-API-DMAC7.html)
JP2023510778A5 (cg-RX-API-DMAC7.html)
JP2022507282A5 (cg-RX-API-DMAC7.html)
CN115175894A (zh) 纳米材料
JP2020536125A5 (cg-RX-API-DMAC7.html)
JP2009535462A (ja) 化学的に異なる末端基を含むポリ(エチレングリコール)
JP2021501754A5 (cg-RX-API-DMAC7.html)
JP2012503621A5 (cg-RX-API-DMAC7.html)
RU2016142510A (ru) Соединения и способы для транс-мембранной доставки молекул
JP7042053B2 (ja) 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
JP2016520312A5 (cg-RX-API-DMAC7.html)
JP2013138681A5 (cg-RX-API-DMAC7.html)
US12059477B2 (en) Nanomaterials
RU2016103695A (ru) СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ
WO2023121975A1 (en) Ionizable amine lipids and lipid nanoparticles
JP2023534206A5 (cg-RX-API-DMAC7.html)
US20250263393A1 (en) Fap inhibitors
US12319644B2 (en) Lipid compound containing carbamate bond and applications thereof
WO2023121970A1 (en) Ionizable amine and ester lipids and lipid nanoparticles